8-K filed July 27, 2026, 9:08 AM ET ticker SRPT CIK 0000873303

leadership confidence high sentiment neutral materiality 0.70

Sarepta names Michael Severino CEO effective July 28; Ingram retires

Sarepta Therapeutics, Inc.

Michael Severino appointed CEO effective July 28, 2026; succeeds Doug Ingram who retires.
Severino receives $1.18M base salary, 110% target bonus, and $35M sign-on equity grant.
Ingram to serve as consultant through Dec 2026 at $15k/month consulting fee.
Severino previously CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie.
Severino also appointed to Sarepta's Board of Directors as Class I director.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Severino

Class I director

SRPT · Sarepta Therapeutics, Inc.

Effective: 2026-07-28
Filed: July 27, 2026, 9:08 AM ET

Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director

Appointed

Michael Severino

Chief Executive Officer

SRPT · Sarepta Therapeutics, Inc.

Effective: 2026-07-28
Filed: July 27, 2026, 9:08 AM ET

On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026

Departed

Douglas Ingram

Chief Executive Officer

SRPT · Sarepta Therapeutics, Inc.

Effective: 2026-07-28
Successor: Michael Severino
Filed: July 27, 2026, 9:08 AM ET

Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.

Departed

Douglas Ingram

member of the Board

SRPT · Sarepta Therapeutics, Inc.

Effective: 2026-07-28
Filed: July 27, 2026, 9:08 AM ET

Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Severino was appointed as Class I director at Sarepta Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Severino was appointed as Chief Executive Officer at Sarepta Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Ingram departed as Chief Executive Officer at Sarepta Therapeutics, Inc..

Action: depart
Role: Chief Executive Officer

Exact text from the filing

Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Ingram departed as member of the Board at Sarepta Therapeutics, Inc..

Action: depart
Role: member of the Board

Exact text from the filing

Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.

View on SEC.gov

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-316995

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.